No Data
No Data
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Cuts Target Price to $35
MiNK Therapeutics Announces New Phase 2 Data For Allo-iNKTs At AACR IO Annual Meeting; Study Involves AgenT-797 Combined With BOT/BAL For Refractory Gastroesophageal Cancer
Express News | Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements
MiNK Therapeutics Regains Full Compliance With Nasdaq Listing Requirements
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Unlock the Full List